Phaseline

Companies › Chongqing Claruvis Pharmaceutical

Chongqing Claruvis Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 2; Neurology, Other; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Recombinant Botulinum Toxin Type A (YY001)–Phase 3Upper Limb Spasticity; Moderate to Severe Glabellar Lines; Upper Limb Spasticity (ULS)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06937944Recombinant Botulinum Toxin Type A (YY001)Phase 3Moderate to Severe Glabellar LinesOtherFeb 2026
NCT06783114Recombinant Botulinum Toxin Type A (YY001)Phase 2Upper Limb SpasticityNeurologySep 2026
NCT07242300Recombinant Botulinum Toxin Type A (YY001)Phase 3Upper Limb Spasticity (ULS)NeurologyDec 2026
NCT07478822Recombinant Botulinum Toxin Type A (YY001)Phase 3Upper Limb SpasticityNeurologyJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Pharmazz Incepta Pharmaceuticals Sandoz Neurona Therapeutics Merz Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.